# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 p...
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 ce...
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $...